胶质瘤化疗药物相关标志分子在胶质瘤与正常脑组织中的丰度比较

目的检测并比较常用胶质瘤化疗药物相关标志分子在胶质瘤组织与正常脑组织中的丰度。方法检测并比较MGMT、ERCCl、TopoⅡα和Stathmin在46例不同病理级别胶质瘤标本及6例正常脑组织中的丰度，比较同一病理级别胶质瘤中这些标志分子的变异度。结果正常脑组织中MGMT和ERCCl的丰度显著高于各级别胶质瘤组织（P〈0．05），而TopoⅡα的丰度则显著低于各级别胶质瘤组织（P〈0．05），Stathmin的丰度在正常脑组织与各级别胶质瘤中均无显著性差异。这4种标志分子的丰度在不同级别胶质瘤之间差异均无统计学意义，而在同一级别胶质瘤中的变异度均较大。结论在胶质瘤组织中，MGMT、ERCCl、TopoⅡα和Stathmin的丰度在不同个体间波动很大，实行胶质瘤的个体化丰度检测和个体化化疗会更有益。

Comparison between glioma and normal brain tissues in abundance of glioma chemotherapeutics-related marker molecules

Objective To detect and compare the abundance of glioma chemotherapeutics-related marker molecules between glioma and normal brain tissues. Methods The abundances of MGMT, ERCC1, topoisomerase Ⅱα （Topo Ⅱα） and Stathmin in 46 gliomas and 6 normal brain tissues were detected and compared, and the variation degrees of the four marker molecules in gliomas with the same pathological grade were compared. Results The abundances of MGMT and ERCC 1 were significantly higher in normal brain tissues than in glioma tissues, while the abundance of Topo II ct was significantly lower in the normal brain tissue than in the glioma tissue, and no significant difference in stathmin abundance was found between normal brain tissues and gliomas. There were no significant differences in 4 marker molecules between the different grades of gliomas, however, there was a bigger variation between the gliomas With the same grade. Conclusions There are considerable differences in abundances of MGMT, ERCC 1, Topo Ⅱα and stathmin in glioma tissue between different individuals, therefore, individualized abundance detection and chemotherapy can be beneficial for the patients.